



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Quick guide

Transitional trials from EudraCT to CTIS (sponsor users)

CTIS Training Programme – Module 23
Version 1.3 – January 2023

Learning Objectives

- Remember what a Transitional trial is.
- Understand how to submit a Transitional trial.
- Understand how to submit notifications and clinical trial results for a Transitional trial.
- Understand the roles and permissions involved.

© European Medicines Agency, 2023

Reproduction and/or distribution of the content of these training materials for non-commercial or commercial purposes is authorised, provided the European Medicines Agency is acknowledged as the source of the materials.

The European Medicines Agency developed this training material to enhance public access to information on the Clinical Trial Information System (CTIS). This material describes a preliminary version of CTIS and may therefore not entirely describe the system as it is at the time of use of this material. The Agency does not warrant or accept any liability in relation to the use (in part or in whole) or the interpretation of the information contained in this training material by third parties.

Record of updated versions

Version	Version description	Date
1.3	Minor changes applied: <ul style="list-style-type: none">• Clarification on transition period and date when CTIS becomes mandatory	January 2023
1.2	Minor changes applied: <ul style="list-style-type: none">• European Commission reference link• Part I 'Estimated Start of Recruitment' information for transitional trials• Information about the EudraCT number for transition trials New content: <ul style="list-style-type: none">• Search Functionality	July 2022
1.1	Training material version published at CTIS go-live	January 2022

European Medicines Agency

Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Telephone +31 (0)88 781 6000

Send a question

www.ema.europa.eu/contact

Clinical Trials Information System (CTIS).

Quick guide: Transitional trials from EudraCT to CTIS (Sponsor users).

© European Medicines Agency, 2023.

Reproduction is authorised provided the source is acknowledged.